Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group announced the proposed listing of its subsidiary, CSPC Innovation, on the Main Board of the Stock Exchange. This move is expected to reduce CSPC’s equity interest in CSPC Innovation by approximately 8.46%, constituting a discloseable transaction under the Listing Rules. The listing is subject to market conditions and regulatory approvals, and if successful, will involve an initial public offering of new H Shares, representing up to 10% of CSPC Innovation’s enlarged share capital. The announcement highlights CSPC’s strategic efforts to enhance its market presence and operational growth through this listing.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products, with a strong emphasis on innovation and market expansion.
Average Trading Volume: 177,252,211
Technical Sentiment Signal: Buy
Current Market Cap: HK$107.2B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.